Vipadenant (BIIB-014)
目录号: A13963
A2A receptor 拮抗剂
Vipadenant,也被称为 BIIB014、CEB-4520,是一种强效、选择性且可口服的腺苷A2A受体拮抗剂,目前正处于帕金森病的开发阶段。Vipadenant 在常用的帕金森病模型中展示了强大的口服活性。
Discription | Vipadenant, also known as BIIB014, CEB-4520, is a potent, selective and orally available adenosine A2A receptor antagonist under development for Parkinson's disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson's disease. |
---|
目录号 | A13963 |
---|---|
分子式 | C16H15N7O |
分子量 | 321.344 |
CAS号 | 442908-10-3 |
SMILES | NC1=NC(C2=CC=CO2)=C(N=NN3CC4=CC=C(N)C(C)=C4)C3=N1 |
其他名称 | BIIB014, BIIB-014, BIIB 014, CEB-4520, CEB 4520, CEB4520, V-2006, V2006, V 2006, VER-11135, VER-A00-11, VER-A00049, VER-ADO-49, Vipadenant |
储存条件 | Store lyophilized at -20ºC, keep desiccated. |